Health
Convalescent plasma treatment added to Australian COVID-19 trials – Medical Xpress
Convalescent plasma has been introduced to the AustralaSian COVID-19 Trial (ASCOT) and Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) clinical trials in a bid to identify the best strategy to treat …
Convalescent plasma has been introduced to the AustralaSian COVID-19 Trial (ASCOT) and Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) clinical trials in a bid to identify the best strategy to treat patients hospitalized with COVID-19.
The first patient was recruited to ASCOT earlier this week at The Royal Melbourne Hospital, while REMAP-CAP is on schedule to recruit critically ill patients in partnering Intensive Care Units in the com…
-
General23 hours agoOf saints and sinners | The Spectator Australia
-
General23 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News13 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
General23 hours agoWhy the nation needs the Nationals to ditch Net Zero